These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 23991629

  • 1. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
    Huang Z, Wan X, Liu J, Deng W, Chen A, Liu L, Liu J, Wei G, Li H, Fang D, Li Y.
    Diabetes Technol Ther; 2013 Oct; 15(10):859-69. PubMed ID: 23991629
    [Abstract] [Full Text] [Related]

  • 2. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [Abstract] [Full Text] [Related]

  • 3. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V, Rosenstock J, Patwardhan R, Salzman A.
    JAMA; 2000 Apr 05; 283(13):1695-702. PubMed ID: 10755495
    [Abstract] [Full Text] [Related]

  • 4. Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study.
    Ke W, Liu L, Liu J, Chen A, Deng W, Zhang P, Cao X, Liao Z, Xiao H, Liu J, Li Y.
    J Diabetes Res; 2016 Apr 05; 2016():6839735. PubMed ID: 26640805
    [Abstract] [Full Text] [Related]

  • 5. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG, Kruszynska YT, Mulford MI, Olefsky JM.
    Diabetes; 1999 Dec 05; 48(12):2414-21. PubMed ID: 10580431
    [Abstract] [Full Text] [Related]

  • 6. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.
    Clin Ther; 2005 Sep 05; 27(9):1383-91. PubMed ID: 16291411
    [Abstract] [Full Text] [Related]

  • 7. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.
    Diabetes Care; 2006 Mar 05; 29(3):554-9. PubMed ID: 16505505
    [Abstract] [Full Text] [Related]

  • 8. Intensive insulin therapy combined with metformin is associated with reduction in both glucose variability and nocturnal hypoglycaemia in patients with type 2 diabetes.
    Zhang Y, Zhao Z, Wang S, Zhu W, Jiang Y, Sun S, Chen C, Wang K, Mu L, Cao J, Zhou Y, Gu W, Hong J, Wang W, Ning G.
    Diabetes Metab Res Rev; 2017 Oct 05; 33(7):. PubMed ID: 28609547
    [Abstract] [Full Text] [Related]

  • 9. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
    Derosa G, Gaddi AV, Piccinni MN, Salvadeo S, Ciccarelli L, Fogari E, Ghelfi M, Ferrari I, Cicero AF.
    Diabetes Obes Metab; 2006 Mar 05; 8(2):197-205. PubMed ID: 16448524
    [Abstract] [Full Text] [Related]

  • 10. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A.
    Diabetes Obes Metab; 2006 Nov 05; 8(6):650-60. PubMed ID: 17026489
    [Abstract] [Full Text] [Related]

  • 11. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.
    Yilmaz H, Gursoy A, Sahin M, Guvener Demirag N.
    Acta Diabetol; 2007 Dec 05; 44(4):187-92. PubMed ID: 17726570
    [Abstract] [Full Text] [Related]

  • 12. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.
    Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MW.
    Clin Ther; 2005 Oct 05; 27(10):1548-61. PubMed ID: 16330291
    [Abstract] [Full Text] [Related]

  • 13. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
    Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AF.
    Pharmacotherapy; 2005 May 05; 25(5):637-45. PubMed ID: 15899724
    [Abstract] [Full Text] [Related]

  • 14. A clinical trial to maintain glycemic control in youth with type 2 diabetes.
    TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F.
    N Engl J Med; 2012 Jun 14; 366(24):2247-56. PubMed ID: 22540912
    [Abstract] [Full Text] [Related]

  • 15. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL, Stewart J, Issa M, Lake B, Melis R.
    Clin Ther; 2005 Oct 14; 27(10):1535-47. PubMed ID: 16330290
    [Abstract] [Full Text] [Related]

  • 16. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
    Lin S, Chen M, Chen W, Lin K, Mu P, Zhu B, Xu W, Wang M, Weng J, Zeng L.
    J Diabetes Res; 2018 Oct 14; 2018():2791584. PubMed ID: 30420969
    [Abstract] [Full Text] [Related]

  • 17. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J.
    J Diabetes; 2017 Oct 14; 9(10):890-893. PubMed ID: 28661564
    [Abstract] [Full Text] [Related]

  • 18. Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment.
    Zeng L, Lu H, Deng H, Mu P, Li X, Wang M.
    Diabetes Technol Ther; 2012 Jan 14; 14(1):35-42. PubMed ID: 21877913
    [Abstract] [Full Text] [Related]

  • 19. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.
    Osei K, Gaillard T, Schuster D.
    Metabolism; 2007 Jan 14; 56(1):24-9. PubMed ID: 17161222
    [Abstract] [Full Text] [Related]

  • 20. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.
    Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H.
    Lancet; 2008 May 24; 371(9626):1753-60. PubMed ID: 18502299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.